Roivant Sciences Ltd. (NASDAQ:ROIV) is Tyro Capital Management LLC’s 6th Largest Position

Tyro Capital Management LLC boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 0.6% during the third quarter, HoldingsChannel.com reports. The firm owned 1,754,976 shares of the company’s stock after acquiring an additional 10,649 shares during the period. Roivant Sciences makes up about 6.4% of Tyro Capital Management LLC’s portfolio, making the stock its 6th largest holding. Tyro Capital Management LLC’s holdings in Roivant Sciences were worth $20,252,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ROIV. nVerses Capital LLC acquired a new position in shares of Roivant Sciences in the second quarter worth $34,000. Gladius Capital Management LP purchased a new stake in shares of Roivant Sciences during the 3rd quarter worth about $35,000. Point72 Hong Kong Ltd acquired a new stake in shares of Roivant Sciences during the 2nd quarter valued at about $36,000. US Bancorp DE grew its stake in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares in the last quarter. Finally, Quarry LP acquired a new position in Roivant Sciences in the second quarter worth approximately $53,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Buying and Selling

In related news, COO Eric Venker sold 100,000 shares of the stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00. Following the completion of the sale, the chief operating officer now owns 617,470 shares in the company, valued at approximately $7,193,525.50. This trade represents a 13.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Financial Lp Qvt sold 876,000 shares of Roivant Sciences stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $11.82, for a total value of $10,354,320.00. Following the sale, the director now directly owns 22,179,358 shares in the company, valued at approximately $262,160,011.56. This trade represents a 3.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,677,309 shares of company stock valued at $43,283,184. Insiders own 7.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. Bank of America upped their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $11.90 on Friday. The firm has a market cap of $8.66 billion, a price-to-earnings ratio of 2.10 and a beta of 1.25. The firm has a fifty day moving average price of $11.87 and a two-hundred day moving average price of $11.43. Roivant Sciences Ltd. has a fifty-two week low of $9.69 and a fifty-two week high of $13.06.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.